ABBV
Price
$230.32
Change
+$5.95 (+2.65%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
397.86B
63 days until earnings call
Intraday BUY SELL Signals
BMY
Price
$50.98
Change
+$2.73 (+5.66%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
100.12B
64 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABBV vs BMY

Header iconABBV vs BMY Comparison
Open Charts ABBV vs BMYBanner chart's image
ABBVIE
Price$230.32
Change+$5.95 (+2.65%)
Volume$37.67K
Capitalization397.86B
Bristol-Myers Squibb
Price$50.98
Change+$2.73 (+5.66%)
Volume$147.27K
Capitalization100.12B
ABBV vs BMY Comparison Chart in %
View a ticker or compare two or three
VS
ABBV vs. BMY commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and BMY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (ABBV: $224.40 vs. BMY: $48.26)
Brand notoriety: ABBV and BMY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 21% vs. BMY: 26%
Market capitalization -- ABBV: $397.86B vs. BMY: $100.12B
ABBV [@Pharmaceuticals: Major] is valued at $397.86B. BMY’s [@Pharmaceuticals: Major] market capitalization is $100.12B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $946.83B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $100.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • BMY’s FA Score: 2 green, 3 red.
According to our system of comparison, ABBV is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 5 bullish TA indicator(s).

  • ABBV’s TA Score: 6 bullish, 4 bearish.
  • BMY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than BMY.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -3.19% price change this week, while BMY (@Pharmaceuticals: Major) price change was -1.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.34%. For the same industry, the average monthly price growth was +3.72%, and the average quarterly price growth was +11.72%.

Reported Earning Dates

ABBV is expected to report earnings on Feb 04, 2026.

BMY is expected to report earnings on Feb 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-1.34% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($398B) has a higher market cap than BMY($100B). ABBV has higher P/E ratio than BMY: ABBV (170.54) vs BMY (16.56). ABBV YTD gains are higher at: 30.696 vs. BMY (-10.443). BMY has higher annual earnings (EBITDA): 15.1B vs. ABBV (14.2B). BMY has less debt than ABBV: BMY (50.9B) vs ABBV (70.5B). ABBV has higher revenues than BMY: ABBV (58.3B) vs BMY (47.7B).
ABBVBMYABBV / BMY
Capitalization398B100B398%
EBITDA14.2B15.1B94%
Gain YTD30.696-10.443-294%
P/E Ratio170.5416.561,030%
Revenue58.3B47.7B122%
Total CashN/AN/A-
Total Debt70.5B50.9B139%
FUNDAMENTALS RATINGS
ABBV vs BMY: Fundamental Ratings
ABBV
BMY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
798
SMR RATING
1..100
1333
PRICE GROWTH RATING
1..100
2448
P/E GROWTH RATING
1..100
551
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (89). This means that BMY’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (98). This means that ABBV’s stock grew significantly faster than BMY’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as BMY (33). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.

ABBV's Price Growth Rating (24) in the Pharmaceuticals Major industry is in the same range as BMY (48). This means that ABBV’s stock grew similarly to BMY’s over the last 12 months.

ABBV's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (51). This means that ABBV’s stock grew somewhat faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVBMY
RSI
ODDS (%)
Bullish Trend 6 days ago
65%
Bearish Trend 6 days ago
46%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
67%
Bearish Trend 6 days ago
52%
Momentum
ODDS (%)
Bearish Trend 6 days ago
46%
Bullish Trend 6 days ago
47%
MACD
ODDS (%)
Bearish Trend 6 days ago
39%
Bullish Trend 6 days ago
44%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
43%
Bullish Trend 6 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
61%
Bullish Trend 6 days ago
51%
Advances
ODDS (%)
Bullish Trend 17 days ago
58%
Bullish Trend 8 days ago
52%
Declines
ODDS (%)
Bearish Trend 14 days ago
43%
Bearish Trend 20 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
64%
Bearish Trend 6 days ago
58%
Aroon
ODDS (%)
Bearish Trend 6 days ago
61%
Bearish Trend 6 days ago
52%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signal:
Gain/Loss:
BMY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IUS57.220.14
+0.24%
Invesco RAFI™ Strategic US ETF
PIM3.33N/A
N/A
Picard Medical Inc
ABI24.94N/A
N/A
VictoryShares Pioneer Asst-Based Inc ETF
SPMD57.60-0.20
-0.35%
State Street SPDR Port S&P 400 Md CpETF
IEDI55.09-0.21
-0.37%
iShares U.S. Consumer Focused ETF

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
-0.32%
PFE - ABBV
58%
Loosely correlated
-0.46%
BMY - ABBV
57%
Loosely correlated
-1.88%
AMGN - ABBV
53%
Loosely correlated
+0.26%
NVS - ABBV
52%
Loosely correlated
+2.59%
BIIB - ABBV
50%
Loosely correlated
+1.51%
More

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
-1.88%
PFE - BMY
67%
Closely correlated
-0.46%
MRK - BMY
58%
Loosely correlated
-0.76%
ABBV - BMY
57%
Loosely correlated
-0.32%
BIIB - BMY
55%
Loosely correlated
+1.51%
AMGN - BMY
54%
Loosely correlated
+0.26%
More